Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Identify Areas for Clinical Differentiation To stand out clinically amidst increasing competition, manufacturers are moving beyond weight loss to explore expanding indications, novel clinical pathways, and additional therapeutic benefits
Iodine deficiency and thyroid disorders
Neurol Med Chir (Tokyo)
Consult a physician before use
Cagrilintide: Long-acting amylin analog explained What cagrilintide is: Synthetic analog of human amylin hormone Also called "pramlintide long-acting" (related compound) Developed by Novo Nordisk Currently investigational (Phase 3 trials) Not yet FDA approved (as of 2024) Weekly subcutaneous injection Natural amylin background: Peptide hormone co-secreted with insulin Made by pancreatic beta cells Released after meals in response to nutrients Important satiety signal Regulates postprandial glucose Deficient in diabetes Why synthetic cagrilintide was developed: Natural amylin very short half-life (minutes) Impractical for treatment Cagrilintide engineered for long duration Weekly dosing vs multiple daily injections Better pharmacokinetics Enhanced stability Learn about peptides , how peptides work , and what are peptides used for at SeekPeptides
2024 Jan;21(1):3-5
